Value of Life Sciences Innovation
Research Program
Value of Life Sciences Innovation
Biomedical advances are at the front lines of transforming healthcare through innovations that benefit countless people. The Value of Life Sciences Innovation (VLSI) program exemplifies the Schaeffer Center’s focus on evidence-based analyses that encourage breakthroughs while developing pricing and reimbursement strategies to help ensure that patients receive the therapies they need.
Program Leadership
Spotlight on PBMs View All
Pharmaceutical Distribution System Economics
U.S. Consumers Overpay for Generic Drugs
Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Experts: Erin Trish, Karen Van Nuys
Featured Perspective
Medicare Drug Price Negotiations Need Something New: A Floor
Adding a floor price mechanism would protect valuable innovation and effectively give future generations of patients a seat at the negotiating table.
Experts: Darius Lakdawalla
Featured White Papers View All
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Experts: Alison Sexton Ward, Karen Van Nuys, Darius Lakdawalla